Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Norma E Farrow"'
Autor:
Matthias Gromeier, Darell D Bigner, Smita K Nair, David Boczkowski, Michael C Brown, Karenia Landa, Sin-Ho Jung, Georgia M Beasley, Norma E Farrow, Maria Angelica Selim, Rami N Al-Rohil, Aaron D Therien, Junheng Gao, Eda K Holl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background We previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients al
Externí odkaz:
https://doaj.org/article/04605eb95ab14089a2829c1d83ca4646
Autor:
Yun Song, John F Thompson, Frances A Collichio, Tasha Hughes, John Vetto, Dale Han, Jonathan Zager, Zeynep Eroglu, Jennifer Downs, David E Gyorki, Nikhil I Khushalani, Alexander van Akkooi, Georgia Beasley, Lisa Kottschade, Hidde M Kroon, Ann Lee, Norma E Farrow, Giorgos Karakousis, Michael Lowe, Avinash Sharma, Kristy K Broman, Amanda Nijhuis, Tina J Hieken, Jeffrey M Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Edmund K Bartlett, Lesly Dossett, Russell S Berman, Emma Stahlie, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, David W Ollila, Roger Olofsson Bagge, Jan Mattsson, Harvey Chai, Jyri Teras, James Sun, Michael J Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial
Externí odkaz:
https://doaj.org/article/5e2609c2e5e44274aabf900f1ff2c1c7
Autor:
Matthias Gromeier, Darell D Bigner, Smita K Nair, Karenia Landa, Sin-Ho Jung, Georgia M Beasley, Norma E Farrow, Maria Angelica Selim, Carol Ann Wiggs, Andrea True Kelly, April KS Salama
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chime
Externí odkaz:
https://doaj.org/article/e28cb6ceb21645b987a84e695f9c4187
Autor:
Brandyn D Lau, Dauryne L Shaffer, Deborah B Hobson, Gayane Yenokyan, Jiangxia Wang, Elizabeth A Sugar, Joseph K Canner, David Bongiovanni, Peggy S Kraus, Victor O Popoola, Hasan M Shihab, Norma E Farrow, Jonathan K Aboagye, Peter J Pronovost, Michael B Streiff, Elliott R Haut
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0181664 (2017)
Venous thromboembolism (VTE) is a common cause of preventable harm in hospitalized patients. While numerous successful interventions have been implemented to improve prescription of VTE prophylaxis, a substantial proportion of doses of prescribed pre
Externí odkaz:
https://doaj.org/article/fffeb89440f04649a27dd4d080ad330c
Autor:
Victor O Popoola, Brandyn D Lau, Hasan M Shihab, Norma E Farrow, Dauryne L Shaffer, Deborah B Hobson, Susan V Kulik, Paul D Zaruba, Kenneth M Shermock, Peggy S Kraus, Peter J Pronovost, Michael B Streiff, Elliott R Haut
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0152084 (2016)
IMPORTANCE:Venous thromboembolism (VTE) is a major cause of morbidity and mortality among hospitalized patients and is largely preventable. Strategies to decrease the burden of VTE have focused on improving clinicians' prescribing of prophylaxis with
Externí odkaz:
https://doaj.org/article/c242c74cbf854ae8888956a03df83ffb
Autor:
Kristy K, Broman, Tasha M, Hughes, Brooke C, Bredbeck, James, Sun, Dennis, Kirichenko, Michael J, Carr, Avinash, Sharma, Edmund K, Bartlett, Amanda A G, Nijhuis, John F, Thompson, Tina J, Hieken, Lisa, Kottschade, Jennifer, Downs, David E, Gyorki, Emma, Stahlie, Alexander, van Akkooi, David W, Ollila, Kristin, O'shea, Yun, Song, Giorgos, Karakousis, Marc, Moncrieff, Jenny, Nobes, John, Vetto, Dale, Han, Meghan, Hotz, Jeffrey M, Farma, Jeremiah L, Deneve, Martin D, Fleming, Matthew, Perez, Kirsten, Baecher, Michael, Lowe, Roger Olofsson, Bagge, Jan, Mattsson, Ann Y, Lee, Russell S, Berman, Harvey, Chai, Hidde M, Kroon, Juri, Teras, Roland M, Teras, Norma E, Farrow, Georgia M, Beasley, Jane Yuet Ching, Hui, Lukas, Been, Schelto, Kruijff, Brandy, Sinco, Amod A, Sarnaik, Vernon K, Sondak, Jonathan S, Zager, Lesly A, Dossett
Publikováno v:
Annals of Surgery. 277(5):1106-1115
Objective: The aim of this study was to determine overall trends and center-level variation in utilization of completion lymph node dissection (CLND) and adjuvant systemic therapy for sentinel lymph node (SLN)-positive melanoma. Summary Background Da
Autor:
Marcelo Cerullo, Hui-Jie Lee, Christopher Kelsey, Norma E. Farrow, Charles D. Scales, Betty C. Tong
Publikováno v:
The Annals of Thoracic Surgery. 115:338-345
Stereotactic body radiation therapy (SBRT) is used to treat stage I non-small cell lung cancer (NSCLC) in nonsurgical candidates, although guidelines specify that inoperability be determined in multidisciplinary fashion. We characterized NSCLC patien
Publikováno v:
Annals of Surgical Oncology. 30:2586-2589
Autor:
Adam C. Berger, Emily Stroobant, Caitlin Silvestri, Austin Eckhoff, Charles M. Intenzo, Georgia M. Beasley, Douglas S. Tyler, Margaret Leddy, Norma E. Farrow
Publikováno v:
J Surg Oncol
BACKGROUND: In 2014, technetium-99m tilmanocept (TcTM) replaced technetium-99m sulfur colloid (TcSC) as the standard lymphoscintigraphy (LS) mapping agent in melanoma patients undergoing sentinel lymph node biopsy (SLNB). The aim of this study was to
Publikováno v:
North Carolina Medical Journal. 82:321-326
BACKGROUND Low-dose chest CT (LDCT) is the only effective screening test for lung cancer. Annual lung cancer screening (LCS) is recommended by the US Preventive Services Task Force (USPSTF) for individuals at high risk for primary lung neoplasm.METHO